Jumia Technologies AG - ADR (JMIA) Stock Price Today
Aura AI Summary
Key Stats
- $704.72MMarket Cap
- -Volume
- Consumer CyclicalSector
- $14.6052W High
- $5.6952W Low
- -Typical Hold Time
- $651.82MEnterprise Value
- -Div Yield
- -Trading Activity
Track Jumia Technologies AG - ADR (JMIA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Jumia Technologies AG - ADR has traded between a low of $5.69 and a high of $14.6, highlighting its annual price range. Buy and sell Jumia Technologies AG - ADR shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Most Recent News
Digital Realty backs Texas Governor Abbott's plan for responsible data center growth amid rising AI demand.
Digital Realty, the largest cloud- and carrier-neutral data center platform, supports Texas Governor Abbott's initiative for responsible and transparent data center investment in Texas. The company emphasizes collaboration with officials and communit...
Verisk Analytics CEO Lee Shavel sells 2,500 shares for $550,000.
Verisk Analytics CEO Lee Shavel has sold 2,500 shares of the company, generating $550,000 from the transaction. This sale may indicate personal portfolio adjustments or strategic financial planning by the CEO. Investors might watch for any further in...
Replimune's stock jumps after FDA approves its first skin cancer drug Tudriqev
Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.